. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug;6(8):734-46. PubMed.


Please login to recommend the paper.


  1. This position paper by Dubois et al. is a long overdue call for reassessing the criteria, assumptions, and procedures for diagnosis of Alzheimer disease. The recommendations of this work group are well reasoned and sound. However, the task of crafting “consensus” criteria will not be easy for several reasons: a) lack of a clear definition of the “disease” or clinical phenomenon; b) tremendous heterogeneity in both clinical and biological phenotypes of the “disease”; and c) lack of or poorly understood causal relationship(s) between the clinical expression of the “disease” and their biological underpinnings.

    In spite of these long-standing problems the field faces, the work group has done an excellent job in laying the foundation for an ongoing effort to refine the criteria that have been used since 1984.

    View all comments by Zaven Khachaturian
  2. The authors are to be congratulated on this paper! It is very timely, the call to incorporate a biological footprint in diagnosis is appropriate, and the elimination of MCI to AD as a binary outcome is most welcome. However, from my perspective, the salient information regarding dementia diagnosis is that an individual has declined in cognitive abilities, relative to previous levels, and that the decline is sufficient to interfere with function in everyday activities. Most importantly, then, we need to know how an individual has changed relative to his/her premorbid cognitive function—this is the principle of intraindividual change. The Core Diagnostic Criterion A proposed by Dubois et al. specifies that there be objective deficit on an episodic memory measure, presumably in comparison with age- and education-matched norms. Rather than judging that individuals have declined relative to previously attained abilities, their test performances are compared with the performances of other persons. Dependence of this interindividual comparison to determine the presence of dementia is flawed on several levels: 1) it does not indicate that the individual's performance has changed from his/her prior performance; 2) it does not indicate whether the cognitive test results relate to impaired everyday function; and 3) depending on where the cutpoint is established, in a normally distributed population some percentile of nondemented individuals will be classified as "impaired." For example, if the cutpoint is 1 SD of the mean, 17 percent will be below the tail; if the cutpoint is 2 SD of the mean, 2.5 percent will be below the tail. On the other side of the coin, some clearly dementing individuals of high intellectual attainment may not be classified as impaired based on cognitive test performance because they still are able to perform at a level above the cutpoint. Moreover, there are many potential confounds (e.g., education, literacy, culture) that affect interpretation of neuropsychological test performance.

    I recognize that my views about the operationalization of diagnostic criteria for MCI/AD are very much in the minority, as the diagnosis most often is on cognitive test scores. I contend, however, that this test-based approach inherently identifies some individuals as having "MCI," for example, when in fact their cognitive abilities have not changed and they continue to function normally. Depending on where the cutpoints are set and the population to which they are applied, the proportion of such non-impaired individuals in the sample will vary, contributing directly to the reported variability in the outcomes of these samples. Basing the diagnosis of impairment on the principle of intraindividual change, on the other hand, is both highly accurate and sensitive in the early detection of symptomatic AD (Storandt et al., 2006). In fact, for the subset of individuals characterized with MCI for whom underlying AD is the cause, MCI is not a risk factor for AD; it is AD in its earliest symptomatic stage. Revised criteria for AD should take into account this knowledge and discard the concept of MCI in favor of etiological diagnoses; for most cases, MCI is early-stage AD (Morris, 2006 ).


    . Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006 Aug 8;67(3):467-73. PubMed.

    . Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. Arch Neurol. 2006 Jan;63(1):15-6. PubMed.

    View all comments by John Morris

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. AD Diagnosis: Time for Biomarkers to Weigh In?
  2. St. Louis: Cognition Pre-dementia—Like eFAD, Like LOAD?
  3. Revised Criteria for Preclinical AD, Exactly as Presented
  4. DC: Biomarkers, Parkinson’s—CAMD Needs All Hands on Deck
  5. Revised Diagnostic Criteria for Alzheimer’s Are Published
  6. Worldwide Quality Control Set to Tame Biomarker Variation
  7. Researchers Join to Draw Posterior Cortical Atrophy Out of Shadows
  8. The EMA Deems Brain Atrophy Valid Trial Selection Measure
  9. CTAD: Turning the Ship Around Toward Early Trials
  10. Alzheimer Activism: How To Modernize Clinical Trials?
  11. Zuers—Meeting Mixes Translational News and Debate
  12. Miami: Is Human Amyloid Imaging Ready for Clinical Trials?
  13. Chicago: The Phase 2 Problem and the Way to a Surrogate, Part 2
  14. Vienna: New Genes, Anyone? ICAD Saves Best for Last
  15. Medical Foods—Food for Thought, But Think Twice
  16. Nutrient Formulation Appears to Grease Memory Function
  17. BACE1 Gets Attention as Potential Alzheimer’s Biomarker
  18. CTE Needs Consensus on Lifetime Diagnosis
  19. Dementia Diagnosis—Are Many Heads Better Than One?
  20. Mistaken Identity—Prion Disease or Alzheimer’s on Fast Forward?
  21. Exosomes Divulge Lysosomal Unrest, Signal AD?
  22. Souvenaid Trial Missed Primary, Partially Met Secondary Endpoints
  23. LipiDiDiet Data Published


  1. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
  2. Together at Last, Top Five Biomarkers Model Stages of AD
  3. Two New Sets of Diagnostic Criteria—Which Is Right for Your Clinic?
  4. Who Should Use the New Diagnostic Guidelines? The Debate Continues

Research Timeline Event

  1. International Working Group revises AD diagnosis, uses biomarkers to capture early stage